Local
BU Researchers Find Blood Proteins That May Signal CTE in Living Patients
A small Boston University study has identified blood biomarkers that could eventually allow doctors to diagnose CTE in living patients, a breakthrough that researchers say could transform clinical care and treatment trials for the neurodegenerative disease.
Boston University researchers have identified blood proteins that may one day allow doctors to diagnose chronic traumatic encephalopathy in living patients, a development the study's senior author calls a potential game-changer for a disease currently confirmed only after death.
The study, published Thursday in the Journal of the American Medical Association, examined blood samples from 21 former football players who competed at the high school, college and professional levels. After the athletes died, researchers analyzed their brain tissue and found that 18 had CTE, a neurodegenerative disease caused by repeated head trauma.
The scientists found that concentrations of a protein called endogenously cleaved microtubule-binding region tau, or eMTBR-tau, were substantially higher in the blood of people with more advanced stages of the disease. Five of the participants with CTE also had Alzheimer's disease, and those individuals showed the highest levels of the biomarker. A second marker used to detect Alzheimer's was absent in patients who had CTE alone, a finding that could eventually help doctors distinguish between the two conditions.
Michael Alosco, a senior author of the study and co-director of clinical research at BU's CTE Center, cautioned that the research is preliminary and requires validation in larger studies. But he said the implications are significant.
"If we can validate our findings and this holds up, it's gonna really change the landscape of clinical research and clinical care," Alosco said.
CTE has been linked to memory problems, aggression, difficulty with impulse control, mood changes and suicidal thoughts. Studies suggest it may affect as many as one in four NFL players. Currently, the disease can be diagnosed only by examining brain tissue after death, which has stymied efforts to develop treatments because researchers cannot recruit living patients for clinical trials.
"This is what we ultimately need to really kind of launch clinical trials," Alosco said.
He estimated that if the findings hold up, a blood test could move toward Food and Drug Administration approval within the next five years. The next steps include larger studies to determine how the biomarker relates to symptoms and brain changes.
"We're at a unique inflection point of entering kind of the next phase of research of CTE where we're closer to diagnosis in the living," Alosco said.
The research adds to a growing body of work at BU's CTE Center, which has become a leading institution in the study of repetitive head trauma and its long-term effects on athletes. A reliable blood test would represent a major shift for families and former players who currently have no way to confirm a diagnosis during life.